Published in BMC Musculoskelet Disord on May 25, 2014
Anti-CD20 antibody therapy and susceptibility to Pneumocystis pneumonia. Infect Immun (2015) 0.83
Immunoglobulin replacement therapy in secondary hypogammaglobulinemia. Front Immunol (2014) 0.83
Spotlight on rituximab in the treatment of antineutrophil cytoplasmic antibody-associated vasculitis: current perspectives. Ther Clin Risk Manag (2015) 0.75
Risk Factors and Adverse Events Poorly Predict Infections and Hypogammaglobulinemia in Granulomatosis with Polyangiitis Patients Receiving Rituximab. Autoimmune Dis (2016) 0.75
The efficacy and safety of rituximab in a chart review study of 15 patients with systemic lupus erythematosus. Clin Rheumatol (2015) 0.75
Perioperative management of drugs commonly used in patients with rheumatic diseases: a review. Clinics (Sao Paulo) (2017) 0.75
Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med (2004) 14.53
Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med (2010) 11.05
Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum (2006) 8.78
Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med (2010) 8.64
Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol (1998) 8.40
The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum (2006) 5.68
Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum (2012) 4.80
Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum (2010) 4.57
Rituximab for refractory Wegener's granulomatosis: report of a prospective, open-label pilot trial. Am J Respir Crit Care Med (2005) 3.04
Safety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French AutoImmunity and Rituximab registry. Arthritis Rheum (2010) 2.68
Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: an open-label extension analysis. Arthritis Rheum (2007) 2.31
Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: Remission, relapse, and re-treatment. Arthritis Rheum (2006) 2.14
Rituximab for remission maintenance in relapsing antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum (2012) 2.05
Rituximab for remission induction and maintenance in refractory granulomatosis with polyangiitis (Wegener's): ten-year experience at a single center. Arthritis Rheum (2012) 1.99
Longterm safety of patients receiving rituximab in rheumatoid arthritis clinical trials. J Rheumatol (2010) 1.91
Recommendations for the use of rituximab in anti-neutrophil cytoplasm antibody-associated vasculitis. Rheumatology (Oxford) (2011) 1.79
Rituximab maintenance therapy for granulomatosis with polyangiitis and microscopic polyangiitis. J Rheumatol (2011) 1.75
A multicenter survey of rituximab therapy for refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum (2009) 1.74
B-cell depletion with rituximab for refractory head and neck Wegener's granulomatosis: a cohort study. Clin Otolaryngol (2009) 1.67
Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients. Ann Rheum Dis (2012) 1.54
Development and validation of a disease extent index for Wegener's granulomatosis. Clin Nephrol (2001) 1.51
Risk factors for severe infections in patients with rheumatoid arthritis treated with rituximab in the autoimmunity and rituximab registry. Arthritis Rheum (2010) 1.47
Incidence of hypogammaglobulinemia in patients receiving rituximab and the use of intravenous immunoglobulin for recurrent infections. Clin Lymphoma Myeloma Leuk (2012) 1.28
Rituximab for refractory granulomatosis with polyangiitis (Wegener's granulomatosis): comparison of efficacy in granulomatous versus vasculitic manifestations. Ann Rheum Dis (2011) 1.24
Impact of rituximab on immunoglobulin concentrations and B cell numbers after cyclophosphamide treatment in patients with ANCA-associated vasculitides. PLoS One (2012) 1.23
Serum immunoglobulins and risk of infection: how low can you go? Semin Arthritis Rheum (2008) 1.14
Severe hypogammaglobulinemia persisting for 6 years after treatment with rituximab combined chemotherapy due to arrest of B lymphocyte differentiation together with alteration of T lymphocyte homeostasis. Int J Hematol (2010) 1.11
Long-term follow-up of relapsing/refractory anti-neutrophil cytoplasm antibody associated vasculitis treated with the lymphocyte depleting antibody alemtuzumab (CAMPATH-1H). Ann Rheum Dis (2007) 1.06
Long-term efficacy and safety of rituximab in refractory and relapsing systemic lupus erythematosus. Nephrol Dial Transplant (2010) 1.00
Rituximab purging and maintenance combined with auto-SCT: long-term molecular remissions and prolonged hypogammaglobulinemia in relapsed follicular lymphoma. Bone Marrow Transplant (2008) 0.94
Rituximab-treated patients have a poor response to influenza vaccination. J Clin Immunol (2012) 0.92
Hypogammaglobulinemia with a selective delayed recovery in memory B cells and an impaired isotype expression after rituximab administration as an adjuvant to autologous stem cell transplantation for non-Hodgkin lymphoma. Eur J Haematol (2006) 0.91
Biological therapy for lupus nephritis-tribulations and trials. Nat Rev Rheumatol (2010) 0.90
Deoxyspergualin in relapsing and refractory Wegener's granulomatosis. Ann Rheum Dis (2008) 0.90
Maintenance rituximab after autologous stem cell transplant for high-risk B-cell lymphoma induces prolonged and severe hypogammaglobulinemia. Bone Marrow Transplant (2005) 0.90
Long-term follow-up of different refractory systemic vasculitides treated with rituximab. Clin Rheumatol (2011) 0.83
Rituximab administration following autologous stem cell transplantation for multiple myeloma is associated with severe IgM deficiency. Blood (2004) 0.81
Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med (2010) 8.64
Immunosuppression for progressive membranous nephropathy: a UK randomised controlled trial. Lancet (2013) 7.03
Genetically distinct subsets within ANCA-associated vasculitis. N Engl J Med (2012) 6.93
microRNA-155 regulates the generation of immunoglobulin class-switched plasma cells. Immunity (2007) 6.72
Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial. Ann Intern Med (2009) 6.61
Competence and competition: the challenge of becoming a long-lived plasma cell. Nat Rev Immunol (2006) 5.22
Foxp3+ follicular regulatory T cells control the germinal center response. Nat Med (2011) 4.83
Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum (2005) 4.21
Granulomatosis with polyangiitis (Wegener's): an alternative name for Wegener's granulomatosis. Arthritis Rheum (2011) 3.60
Human SNP links differential outcomes in inflammatory and infectious disease to a FOXO3-regulated pathway. Cell (2013) 3.49
FcgammaRIIb controls bone marrow plasma cell persistence and apoptosis. Nat Immunol (2007) 3.04
A CD8+ T cell transcription signature predicts prognosis in autoimmune disease. Nat Med (2010) 2.88
B-cell-depleting induction therapy and acute cellular rejection. N Engl J Med (2009) 2.56
Outcome of ANCA-associated renal vasculitis: a 5-year retrospective study. Am J Kidney Dis (2003) 2.40
Brief Report: long-term outcome of a randomized clinical trial comparing methotrexate to cyclophosphamide for remission induction in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum (2012) 2.19
Copy number of FCGR3B, which is associated with systemic lupus erythematosus, correlates with protein expression and immune complex uptake. J Exp Med (2008) 2.13
Rituximab for remission maintenance in relapsing antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum (2012) 2.05
Loss of function of a lupus-associated FcgammaRIIb polymorphism through exclusion from lipid rafts. Nat Med (2005) 2.01
FcgammaRIIb balances efficient pathogen clearance and the cytokine-mediated consequences of sepsis. J Exp Med (2004) 1.95
The structural basis for serotype-specific neutralization of dengue virus by a human antibody. Sci Transl Med (2012) 1.95
Renal vasculitis in Japan and the UK--are there differences in epidemiology and clinical phenotype? Nephrol Dial Transplant (2008) 1.85
Clinical and histologic determinants of renal outcome in ANCA-associated vasculitis: A prospective analysis of 100 patients with severe renal involvement. J Am Soc Nephrol (2006) 1.82
Plasma exchange for renal vasculitis and idiopathic rapidly progressive glomerulonephritis: a meta-analysis. Am J Kidney Dis (2010) 1.81
Recommendations for the use of rituximab in anti-neutrophil cytoplasm antibody-associated vasculitis. Rheumatology (Oxford) (2011) 1.79
Renal histology in ANCA-associated vasculitis: differences between diagnostic and serologic subgroups. Kidney Int (2002) 1.78
Generating an iPSC bank for HLA-matched tissue transplantation based on known donor and recipient HLA types. Cell Stem Cell (2012) 1.75
A multicenter survey of rituximab therapy for refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum (2009) 1.74
Microarray analysis of human leucocyte subsets: the advantages of positive selection and rapid purification. BMC Genomics (2007) 1.74
SIGN-R1 contributes to protection against lethal pneumococcal infection in mice. J Exp Med (2004) 1.73
Comparison of the epidemiology of anti-neutrophil cytoplasmic antibody-associated vasculitis between Japan and the U.K. Rheumatology (Oxford) (2011) 1.59
Systemic lupus erythematosus-associated defects in the inhibitory receptor FcgammaRIIb reduce susceptibility to malaria. Proc Natl Acad Sci U S A (2007) 1.55
Analysis of a wild mouse promoter variant reveals a novel role for FcγRIIb in the control of the germinal center and autoimmunity. J Exp Med (2012) 1.55
Predicting HLA class I alloantigen immunogenicity from the number and physiochemical properties of amino acid polymorphisms. Transplantation (2009) 1.49
Gene expression profiling of CD8+ T cells predicts prognosis in patients with Crohn disease and ulcerative colitis. J Clin Invest (2011) 1.47
Determinants of outcome in ANCA-associated glomerulonephritis: a prospective clinico-histopathological analysis of 96 patients. Kidney Int (2002) 1.44
CD22: an inhibitory enigma. Immunology (2007) 1.43
Distinct cell-specific control of autoimmunity and infection by FcgammaRIIb. J Exp Med (2008) 1.43
A defunctioning polymorphism in FCGR2B is associated with protection against malaria but susceptibility to systemic lupus erythematosus. Proc Natl Acad Sci U S A (2010) 1.41
Efficient inhibition of miR-155 function in vivo by peptide nucleic acids. Nucleic Acids Res (2010) 1.41
Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis with poor kidney function: a subgroup analysis of the Aspreva Lupus Management Study. Am J Kidney Dis (2013) 1.41
Copy number, linkage disequilibrium and disease association in the FCGR locus. Hum Mol Genet (2010) 1.41
Ten-year experience of selective omission of the pretransplant crossmatch test in deceased donor kidney transplantation. Transplantation (2010) 1.41
A phase 1, single-dose study of fresolimumab, an anti-TGF-β antibody, in treatment-resistant primary focal segmental glomerulosclerosis. Kidney Int (2011) 1.37
Granulomatosis with polyangiitis (Wegener's): an alternative name for Wegener's granulomatosis. Ann Rheum Dis (2011) 1.33
Efficacy of rituximab in 164 patients with biopsy-proven lupus nephritis: pooled data from European cohorts. Autoimmun Rev (2011) 1.27
Dendritic cell stimulation by mycobacterial Hsp70 is mediated through CCR5. Science (2006) 1.27
Long-term follow-up of patients with severe ANCA-associated vasculitis comparing plasma exchange to intravenous methylprednisolone treatment is unclear. Kidney Int (2013) 1.24
CD4+CD25+ regulatory T cells do not significantly contribute to direct pathway hyporesponsiveness in stable renal transplant patients. J Am Soc Nephrol (2003) 1.23
Alemtuzumab (CAMPATH 1H) induction therapy in cadaveric kidney transplantation--efficacy and safety at five years. Am J Transplant (2005) 1.22
Interleukin 4 reduces expression of inhibitory receptors on B cells and abolishes CD22 and Fc gamma RII-mediated B cell suppression. J Exp Med (2002) 1.22
FcgammaRIIB, FcgammaRIIIB, and systemic lupus erythematosus. Ann N Y Acad Sci (2010) 1.21
The contribution of genetic variation and infection to the pathogenesis of ANCA-associated systemic vasculitis. Arthritis Res Ther (2010) 1.20
B cell inhibitory receptors and autoimmunity. Immunology (2003) 1.19
Pulmonary renal syndrome: a 4-year, single-center experience. Am J Kidney Dis (2002) 1.18
Revisiting the classification of clinical phenotypes of anti-neutrophil cytoplasmic antibody-associated vasculitis: a cluster analysis. Ann Rheum Dis (2012) 1.17
Differential targeting of viral components by CD4+ versus CD8+ T lymphocytes in dengue virus infection. J Virol (2012) 1.17
Novel expression signatures identified by transcriptional analysis of separated leucocyte subsets in systemic lupus erythematosus and vasculitis. Ann Rheum Dis (2009) 1.16
Health-related quality of life in patients with newly diagnosed antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Care Res (Hoboken) (2011) 1.16
Regulation by CD25+ lymphocytes of autoantigen-specific T-cell responses in Goodpasture's (anti-GBM) disease. Kidney Int (2003) 1.15
High prevalence of autoantibodies to hLAMP-2 in anti-neutrophil cytoplasmic antibody-associated vasculitis. J Am Soc Nephrol (2012) 1.15
Genome-wide methylation analyses of primary human leukocyte subsets identifies functionally important cell-type-specific hypomethylated regions. Blood (2013) 1.15
HSP70 peptide binding mutants separate antigen delivery from dendritic cell stimulation. Immunity (2004) 1.14
Low-affinity Fcgamma receptors, autoimmunity and infection. Expert Rev Mol Med (2009) 1.14
Complement abnormalities in acquired lipodystrophy revisited. J Clin Endocrinol Metab (2008) 1.10
Chances of renal recovery for dialysis-dependent ANCA-associated glomerulonephritis. J Am Soc Nephrol (2007) 1.10
Tubular lesions predict renal outcome in antineutrophil cytoplasmic antibody-associated glomerulonephritis after rituximab therapy. J Am Soc Nephrol (2011) 1.10
Mycophenolate mofetil in anti-neutrophil cytoplasm antibodies-associated systemic vasculitis. Nephron Clin Pract (2005) 1.08
Adverse events during intrahospital transport of critically ill patients: incidence and risk factors. Ann Intensive Care (2013) 1.08
Maintenance triple immunosuppression with cyclosporin A, mycophenolate sodium and steroids allows prolonged survival of primate recipients of hDAF porcine renal xenografts. Xenotransplantation (2003) 1.06
B-cell depletion in the treatment of lupus nephritis. Nat Rev Nephrol (2012) 1.05
The accuracy of diagnostic coding for acute kidney injury in England - a single centre study. BMC Nephrol (2013) 1.03
A cross-sectional study of the Birmingham Vasculitis Activity Score version 3 in systemic vasculitis. Rheumatology (Oxford) (2010) 1.02
Contrasting genetic association of IL2RA with SLE and ANCA-associated vasculitis. BMC Med Genet (2009) 1.01
Magnetic resonance imaging with hyperpolarized [1,4-(13)C2]fumarate allows detection of early renal acute tubular necrosis. Proc Natl Acad Sci U S A (2012) 1.01
Antineutrophil cytoplasm antibody-associated vasculitis: recent developments. Kidney Int (2013) 1.00
Genetic susceptibility to systemic lupus erythematosus protects against cerebral malaria in mice. Proc Natl Acad Sci U S A (2010) 1.00
Long-term efficacy and safety of rituximab in refractory and relapsing systemic lupus erythematosus. Nephrol Dial Transplant (2010) 1.00
New methods to clean ICU rooms. Infect Disord Drug Targets (2011) 1.00
Granulomatosis with polyangiitis (Wegener's): an alternative name for Wegener's granulomatosis. J Am Soc Nephrol (2011) 0.98
Fulminant hemophagocytic lymphohistiocytosis induced by pandemic A (H1N1) influenza: a case report. J Med Case Rep (2011) 0.98
ACE inhibitor and angiotensin receptor-II antagonist prescribing and hospital admissions with acute kidney injury: a longitudinal ecological study. PLoS One (2013) 0.97